Carmot Therapeutics, Inc.

5 articles with Carmot Therapeutics, Inc.

• Carmot to Receive Royalty Payments Upon Sales of Amgen’s FDA Approved First-in-class KRAS G12C Inhibitor, LUMAKRAS™ (sotorasib); Further Demonstrates the Value of Carmot’s Therapeutic Platform

  6/29/2021

  Carmot Therapeutics, Inc., a clinical-stage biotechnology company applying its proprietary therapeutic platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer, announced that in connection with the recent U.S. FDA approval and commercial launch of Amgen’s LUMAKRAS, Carmot is eligible to receive royalty payments from future sales.

• Carmot Therapeutics Initiates the Clinical Program for CT-388, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Patients with Type 2 Diabetes

  6/24/2021

  Carmot Therapeutics, Inc. announced today the initiation of the phase 1 study for CT-388, a once weekly, fully biased dual GLP-1 and GIP receptor modulator, in otherwise healthy overweight and obese participants.

• Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 Diabetes

  5/4/2021

  Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its proprietary Chemotype Evolution (CE) technology to discover and develop disease-modifying therapies in metabolic disease and cancer, announced today U.S. Food and Drug Administration (FDA) clearance of an IND application for CT-868, Carmot’s dual GLP-1 and GIP receptor modulator.

• Carmot Therapeutics Expands Leadership Team With Appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and Executive Vice President of R&D

  3/17/2021

  Carmot Therapeutics, Inc. (Berkeley, CA), a clinical stage biotechnology company advancing transformative therapies for patients with metabolic diseases, announced today the appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and EVP of R&D, and member of the executive leadership team. “Dr. Cha

• Carmot Therapeutics Expands Leadership Team and Closes $47 Million Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies

  9/30/2020

  Carmot Therapeutics, Inc., a biotechnology company focused on bringing transformative therapies to patients with metabolic diseases, announced a $47 million series C financing.